CD4 and neoplasm: We next decided to use mice with the tamoxifen-inducible CD4+ T-cell-specific deletion of Bcl-6 (Bcl6fl/flCD4CreER) to define the impact of Bcl-6 deletion on the early and late stage of anti-tumor CD4+ T-cell response to M002 treatment (Fig. 4g).